Insulin Delivery Articles & Analysis
18 news found
Advancements in drug delivery technology have paved the way for more efficient and targeted treatment options. ...
(the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage, insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced an update on the development of its initial insulin pump product. ...
(the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage, insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced that Jeb Besser, the Company's Chief Executive Officer, will be participating in the following investor conferences: Piper ...
(the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage, insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today provided an update on its insulin pump product. ...
Kevin will have a very significant role in Modular Medical's strategic direction and growth," said Paul DiPerna, Modular Medical's President and Chief Technology Officer. "I believe Modular Medical's insulin delivery platform represents a tremendous opportunity to bring an easy-to-use, cost-effective insulin delivery system to ...
(the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage, insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced that Jeb Besser, the Company's Chief Executive Officer, is scheduled to present at the LD Micro Invitational XII Investor ...
About Type 1 Diabetes T1D results from the autoimmune destruction of insulin-producing islet cells in the pancreas, leading to loss of insulin production and impairment of blood glucose control. The absence of insulin leads to abnormalities in how the body processes nutrients, leading to high blood glucose levels. ...
At Day 90, stimulated C-peptide increased to a peak of 202 pmol/L, indicating that VX-880 restored glucose-responsive insulin production. At Day 150, HbA1c decreased to 7.1% compared to a baseline of 7.5%, and exogenous insulin use decreased by 30%. ...
Modular Medical, Inc., (NASDAQ:MODD) (the "Company" or "Modular Medical"), a development-stage insulin pump company focused on providing insulin delivery without complexity to increase pump adoption and reduce the burden of diabetes care for clinicians and individuals living with diabetes, announced today the pricing of its underwritten public ...
(the "Company" or "Modular Medical") (OTCQB:MODD), a development-stage insulin pump company focused on providing insulin delivery without complexity to increase pump adoption and reduce the burden of diabetes care for clinicians and individuals living with diabetes, today announced the expansion of its Board of Directors with the appointment of ...
(the "Company") (OTCQB:MODD), a development-stage insulin pump company focused on providing insulin delivery without complexity to increase pump adoption and reduce the burden of diabetes care for clinicians and individuals living with diabetes, today announced a "reverse split" of its shares of common stock at a ratio of 1-for-3. ...
(OTCQB:MODD), a development-stage insulin pump company focused on providing insulin delivery without complexity to increase pump adoption and reduce the burden of diabetes care for clinicians and individuals living with diabetes, today announced the expansion of its executive team with the appointment of Lynn O'Connor Vos as its new Chief ...
He currently serves as president & CEO of CeQur SA, a medical device company specializing in insulin delivery systems, and has served in executive leadership roles for multiple global health leaders including global president of spine at Stryker, vice president of global sales & marketing at Bausch + Lomb, and vice president of sales and Kyphon. ...
CeQur®, a medical device company committed to simplifying the lives of people with diabetes by revolutionizing insulin-delivery solutions, today announced the appointments of Rick Doubleday and Meret Gaugler, Ph.D., to its Board of Directors. ...
The company is developing products to optimize insulin dosing and provide automated insulin delivery for people with insulin-requiring diabetes. ...
CeQur Raises $115 Million Series C5 Financing to Support Commercialization and Scale-Up of Automated Manufacturing for CeQur Simplicity Wearable Insulin-Delivery Device. CeQur, a medical device company committed to simplifying the lives of people with diabetes by revolutionizing insulin-delivery solutions, today announced the ...
— a medical technology company developing and aiming to commercialize the world's first fully automated bionic pancreas today announced that its bionic pancreas glucose control algorithms that use lifelong autonomous learning were deployed in a pilot study comparing usual care with automated insulin-only and bihormonal (insulin and glucagon) ...
The transaction includes an exclusive worldwide license for the wearable, on-demand insulin delivery system previously known as OneTouch Via™. The Calibra system enables people with diabetes to discreetly and conveniently deliver rapid-acting insulin at ...